The GLP-1 drugs are all the rage, but are they worth the hype? Dr. David Harris, a Madison-based surgeon, thinks not. In a recent interview, Harris warns that the popularity of these drugs, like Ozempic, Wegovy, and Zepbound, is outpacing the science. While they can be safe and effective when prescribed and monitored by a healthcare provider, the growing demand, high costs, and intermittent shortages have led to a market for compounded and gray-market versions online, raising concerns about product quality, dosing, and safety. Harris emphasizes that these medications are not a one-size-fits-all solution and should be paired with medical supervision and lifestyle changes. He argues that obesity is a chronic problem that requires chronic solutions, and GLP-1s are incredibly effective at helping patients lose weight and avoid health complications. However, he also notes that there are some patients who do not respond to these medications and that weight recurrence after stopping them is universal. This can lead to psychological damage and guilt in patients. Harris also highlights the inequity in healthcare access, as some patients cannot afford clinically-approved GLP-1 medications and may turn to other, less safe options. He believes that there is a real lack of understanding among patients about the mechanism of action and the potential risks and benefits of these drugs. Overall, Harris urges patients to discuss weight management treatment with medical providers and to be cautious about the sources of these medications.
